Overview

First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, open, randomized controlled Phase II clinical study to evaluate the efficacy and safety of intratumoral injection of OH2 combined with capecitabine for first-line maintenance of advanced colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Wuhan Binhui Biotechnology Co., Ltd.
Treatments:
Bevacizumab
Capecitabine